PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research

Overview: Principle and Setup of PF-562271 HCl in Cancer Research

PF-562271 HCl, provided by APExBIO, is a highly potent, ATP-competitive, and reversible inhibitor specifically targeting focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2). FAK plays a central role in the focal adhesion kinase signaling pathway, governing cell adhesion, migration, survival, and ultimately influencing tumor growth and metastasis. Pyk2, a FAK homolog, shares a similar regulatory landscape in the tumor microenvironment, making their dual inhibition a strategic target for cancer research and therapeutic development.

With an impressive IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, PF-562271 HCl demonstrates approximately 10-fold selectivity for FAK over Pyk2 and over 100-fold selectivity against other kinases (with the exception of certain cyclin-dependent kinases). In preclinical models, it effectively inhibits FAK phosphorylation, with an EC₅₀ of 93 ng/mL, correlating with robust tumor growth inhibition and modulation of the tumor microenvironment. The compound is supplied as a solid, is highly soluble in DMSO (≥26.35 mg/mL with gentle warming), and is insoluble in water or ethanol.

Why Target FAK/Pyk2?

FAK/Pyk2 kinases are instrumental in orchestrating the interplay between tumor cells and their microenvironment. Inhibiting these kinases disrupts downstream signaling cascades that promote tumor survival, angiogenesis, immune evasion, and metastatic potential. As such, the use of a selective, reversible focal adhesion kinase inhibitor like PF-562271 HCl is invaluable for dissecting these pathways and evaluating anti-cancer strategies in both in vitro and in vivo settings.

Step-by-Step Experimental Workflow: Optimizing PF-562271 HCl Applications

1. Compound Preparation and Handling

• Store PF-562271 HCl solid at -20°C in a desiccated environment.
• For solution preparation, dissolve the compound in DMSO at the desired stock concentration (up to ≥26.35 mg/mL), applying gentle warming if needed. Avoid water or ethanol as solvents to maintain compound integrity.
• Prepare aliquots to prevent repeated freeze-thaw cycles and use solutions promptly, as long-term storage can reduce activity.

2. In Vitro Application: Cell Culture Studies

• Seed cancer cell lines (e.g., melanoma, breast, or prostate carcinoma) as per experimental design.
• Treat with PF-562271 HCl at nanomolar concentrations, typically within the 1–500 nM range, depending on cell line sensitivity and desired endpoint (e.g., FAK phosphorylation inhibition, cell migration assays).
• Monitor effects on FAK/Pyk2 phosphorylation by Western blotting, immunofluorescence, or ELISA. Quantitative Western blot analysis, as seen in Anichini et al., 2022, can confirm modulation of immune and signaling gene signatures in treated cells.

3. In Vivo Application: Tumor Xenograft Models

• Implant tumor cells subcutaneously or orthotopically into immunocompromised mice.
• Administer PF-562271 HCl systemically (e.g., intraperitoneal injection) at dosing regimens informed by pharmacokinetic profiles and prior literature, ensuring plasma levels sufficient to inhibit FAK phosphorylation (target EC₅₀: 93 ng/mL).
• Assess endpoints such as tumor volume, metastatic burden, and changes in tumor microenvironment composition using histological and molecular analyses.

4. Combination Approaches

• PF-562271 HCl can be combined with immunomodulatory agents (e.g., checkpoint inhibitors, epigenetic drugs) to probe synergistic effects on tumor immune signatures and response rates.
• Experimental designs should include matched control and combination arms, with appropriate immunophenotyping and gene expression profiling to monitor outcomes.

Advanced Applications and Comparative Advantages

Dissecting FAK/Pyk2 Signaling in Tumor and Stromal Compartments

PF-562271 HCl’s high selectivity and reversibility allow researchers to distinguish FAK- and Pyk2-specific effects with minimal off-target interference. This is particularly valuable for:

• Tumor Microenvironment Modulation: By inhibiting FAK, researchers can study changes in stromal cell recruitment, extracellular matrix remodeling, and immune cell infiltration. This is complemented by the findings of Anichini et al. (2022), who showed that targeting upstream regulators—including kinases—can induce immune-related gene expression signatures relevant for immunotherapy design.
• Metastasis Suppression: The inhibitor’s robust performance data in previously published resources highlight its role in blocking metastatic dissemination by impairing cell motility and invasion, extending the utility of FAK/Pyk2 inhibition beyond primary tumor growth control.
• Biomarker-Driven Oncology: PF-562271 HCl supports the development of predictive biomarkers for patient stratification, as explored in translational oncology reviews that advocate for integrated, personalized research strategies.

Comparative Insights: Extending and Contrasting Literature

• Protein Kinase A Inhibitor article confirms the nanomolar potency and reversible, ATP-competitive mechanism of PF-562271 HCl, reinforcing its suitability for precise, short-term pathway modulation versus irreversible covalent inhibitors.
• The Versatile FAK/Pyk2 Inhibitor review emphasizes the compound’s unique performance in both drug discovery and mechanistic studies, complementing its applied value described here.

Troubleshooting and Optimization Tips

Solubility and Handling

• Always use DMSO for stock solutions. If precipitation occurs, gently re-warm and vortex to redissolve. Avoid repeated freeze-thaw cycles by aliquoting stocks.
• Prepare working dilutions fresh for each experiment to prevent degradation; store stock solutions at -20°C for short-term use only.

Experimental Design Considerations

• Optimize dosing based on cell line or animal model sensitivity. Start with concentrations near the IC₅₀ for FAK (1.5 nM) and escalate if required by endpoint assays.
• Include appropriate controls: DMSO vehicle, untreated, and alternative kinase inhibitors to delineate specificity.
• For combination regimens, ensure no adverse solubility or chemical interactions between agents.

Data Interpretation and Validation

• Validate FAK and Pyk2 phosphorylation status post-treatment to confirm pathway inhibition. Western blot quantification is recommended for robust, reproducible results.
• Monitor off-target effects via kinome profiling or transcriptomic analyses, especially if using higher concentrations where selectivity may diminish.

Common Issues and Solutions

• Low Inhibitory Response: Check compound integrity and expiration; verify that DMSO stocks are freshly prepared and fully dissolved.
• Cell Toxicity Unrelated to FAK/Pyk2 Inhibition: Lower the dose or reduce DMSO exposure; confirm specificity with genetic knockdown controls.
• Variability in In Vivo Models: Monitor plasma levels to ensure sufficient systemic exposure, and adjust dosing or frequency as required.

Future Outlook: PF-562271 HCl in Next-Generation Cancer Research

The strategic use of PF-562271 HCl is poised to advance the next wave of cancer research. As highlighted in recent translational oncology reviews and in the immunogenomic analysis by Anichini et al., targeted inhibition of kinases like FAK/Pyk2 can modulate not only tumor cell-intrinsic properties but also the tumor microenvironment and immune landscape. This opens opportunities for combinatorial approaches with immunotherapies and epigenetic modulators, enabling researchers to design more effective, biomarker-driven treatment strategies.

Emerging applications also include high-content screening for resistance mechanisms, integration with single-cell omics, and leveraging the inhibitor for spatially resolved tumor microenvironment studies. The robust selectivity and reversibility of PF-562271 HCl ensure that it will remain a cornerstone in both basic mechanistic investigations and translational therapeutic development.

Learn More and Source with Confidence

To integrate this best-in-class PF-562271 HCl FAK/Pyk2 inhibitor into your workflow, rely on APExBIO for quality and technical support. Its proven performance, reproducibility, and comprehensive documentation make it the preferred choice for precision-driven cancer research projects worldwide.